Edition:
United States

Oncolys Biopharma Inc (4588.T)

4588.T on Tokyo Stock Exchange

792JPY
1:18am EDT
Change (% chg)

¥3 (+0.38%)
Prev Close
¥789
Open
¥783
Day's High
¥797
Day's Low
¥782
Volume
46,600
Avg. Vol
123,355
52-wk High
¥2,070
52-wk Low
¥767

Latest Key Developments (Source: Significant Developments)

Oncolys Biopharma says exercise of options
Friday, 21 Apr 2017 04:43am EDT 

April 21 (Reuters) - Oncolys Biopharma Inc <4588.T>:.  Full Article

Oncolys BioPharma plans capital alliance with bio firm in vaccine business
Wednesday, 29 Mar 2017 02:30am EDT 

Oncolys BioPharma Inc <4588.T> : Says the company plans to enter into a capital alliance with University of Washington-originated bio firm Precision Virologics Inc which is engaged in R&D of vaccine for emerging infectious disease, in April . Says co was granted to own right of veto regarding all projects of Precision Virologics in Asia area . Co will use $500,000 to acquire shares issued by Precision Virologics, and will own about 14 percent stake in it after transaction .Business expects to initiate since April.  Full Article

Oncolys Biopharma signs joint research agreement for next generation telomelysin with Osaka University
Tuesday, 28 Mar 2017 02:25am EDT 

Oncolys Biopharma Inc <4588.T>:Says it signed a joint research agreement for design and production of next generation telomer ricin and next generation telome scan with Osaka University.  Full Article

Wonik Cube to sell Oncolys BioPharma for 10.25 bln won
Monday, 5 Dec 2016 08:31pm EST 

Wonik Cube Corp <014190.KQ> : Says it will sell its entire 712,900 shares of Oncolys BioPharma, which is engaged in pharmaceuticals development in Japan, to recoup investment funds . Transaction amount is 10.25 billion won .Says it will hold 0 percent stake in Oncolys BioPharma, after the transaction.  Full Article

Oncolys BioPharma signs exclusive license agreement with Jiangsu Hengrui Medicine on OBP-301 in China
Wednesday, 30 Nov 2016 04:16am EST 

Oncolys BioPharma Inc <4588.T> : Says co enters into exclusive license agreement with Jiangsu Hengrui Medicine Co Ltd for OBP-301, valid in China mainland, Hong Kong and Macao .Previous plan was disclosed on May 20.  Full Article

Oncolys BioPharma applies phase II clinical trial of OBP-301 in U.S
Wednesday, 31 Aug 2016 02:27am EDT 

Oncolys BioPharma Inc <4588.T>: Says it submitted clinical trial plan (protocol) to the United States Food and Drug Administration for phase II clinical trial of oncolytic virus OBP-301 (Telomelysin®) in U.S .Says unresectable or metastatic malignant melanoma is the target of the clinical trial.  Full Article

Oncolys BioPharma to get patent for production method of OBP-601 (Censavudine) in Europe
Monday, 29 Aug 2016 02:17am EDT 

Oncolys BioPharma Inc <4588.T>: Says it to receive patent for production method of OBP-601 (Censavudine) in Europe .Says OBP-601 (Censavudine) is under research and development as HIV infection treatment drug.  Full Article

Oncolys BioPharma to set up unit Oncolys USA
Friday, 19 Aug 2016 02:22am EDT 

Oncolys BioPharma Inc <4588.T>: Says it to set up a wholly owned subsidiary named Oncolys USA Inc in September .Says the new unit to be engaged in business development and research development of pharmaceuticals and diagnostics.  Full Article

Oncolys Biopharma announces joint research agreement with Kyoto Prefectural University of Medicine
Thursday, 18 Aug 2016 02:00am EDT 

Oncolys Biopharma Inc <4588.T>:Says it approved a new joint research agreement with a research group led by professor of Kyoto Prefectural University of Medicine, to study the scar removing method after glaucoma operation.  Full Article

Oncolys Biopharma to jointly research on OBP-301 with Japan-based university
Tuesday, 5 Jul 2016 02:10am EDT 

Oncolys Biopharma Inc <4588.T>:Says it to jointly research with a research group of a Japan-based university, regarding combinational effect of oncolytic virus OBP-301 (Telomelysin) and checkpoint inhibitor.  Full Article

More From Around the Web

BRIEF-Oncolys Biopharma says exercise of options

* Says 2,450 units of its 15th series options were exercised to 245,000 shares of its common stock from April 1 to April 21